GGrantIndex
Sort

326,823 grants matching clinical trial

Duke SPORE in Brain Cancer

$1,984,462
John H Sampson · Duke University · P50 · FY2020 · CA

Longitudinal validation of retinal biomarkers against cerebral imaging in preclinical Alzheimer's disease

$1,984,309
Jessica Alber · University Of Rhode Island · R01 · FY2025 · AG

Upstate Carolina Community Clinical Oncology Program

$1,984,251
James D Bearden · Spartanburg Regional Medical Center · U10 · FY2006 · CA

Two-Stage Genome-Wide Association Study in Systemic Sclerosis

$1,984,223
Maureen Maureen Mayes · University Of Texas Hlth Sci Ctr Houston · R01 · FY2008 · AR

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)

$1,984,101
Judith S Hochman · New York University School Of Medicine · R01 · FY2022 · HL

Gastroparesis Clinical Research Consortium - Data Coordinating Center

$1,984,099
James A Tonascia · Johns Hopkins University · U01 · FY2010 · DK

ADULT AIDS CLINICAL TRIALS UNIT

$1,984,093
Indiana Univ-Purdue Univ At Indianapolis · U01 · FY2001 · AI

IMPACTA PERU CLINICAL TRIALS UNIT

$1,984,088
Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2016 · AI

A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

$1,984,084
Laurie Sower · Chrysalis Biotherapeutics, Inc. · N01 · FY2018 · AI

Genetic Approaches to Cancer Immunotherapy

$1,984,035
Michel Sadelain · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA

SCCOR in translational research in Acute Lung Injury

$1,983,955
University Of California San Francisco · P50 · FY2005 · HL

Pharmacological Treatment of Retinal Diseases

$1,983,634
Krzysztof Palczewski · Case Western Reserve University · R24 · FY2012 · EY

TECHNICAL INFORMATION RESEARCH RESOURCES FOR CANCER PREVENTIVE AGENT DEVELOPMENT

$1,983,627
Caroline C Sigman · Ccs Associates, Inc. · N02 · FY2015 · CA

The CAPTURE Study: Validating a unique COPD screening tool in primary care

$1,983,602
Fernando J Martinez · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · HL

High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials

$1,983,570
Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai · U24 · FY2023 · CA

A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

$1,983,531
Anthony Andrew Oliva · Longeveron, Llc · R44 · FY2019 · AG

TREATMENT RESEARCH CENTER--BEHAVIORAL PHARMACOLOGY

$1,983,351
Johns Hopkins University · P50 · FY2000 · DA

Impact of FGF21 on healthspan and lifespan

$1,983,293
Vishwa Deep Dixit · Yale University · P01 · FY2020 · AG

Involvement Of Human Viruses Associated With Chronic Neurologic Disease

$1,983,212
Steven Jacobson · National Institute Of Neurological Disorders And Stroke · Z01 · FY2008 · NS

Molecular Genetics of Fanconi Anemia

$1,983,074
Robb E Moses · Oregon Health & Science University · P01 · FY2006 · HL

Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis

$1,982,861
Frank Sciavolino · Thetis Pharmaceuticals, Llc · R44 · FY2020 · DK

Product Development and Manufacture

$1,982,812
Robert T McNally · Geovax, Inc. · U19 · FY2009 · AI

RSK3 Anchoring Disruptor Therapy for Heart Failure

$1,982,787
Federico Cividini · Cardiac Rsk3 Inhibitors, Llc · R44 · FY2024 · HL

Off-the-Shelf Immune Effector Cells for Hematological Malignancies

$1,982,660
John E Wagner · University Of Minnesota · P01 · FY2024 · CA

CANCER CENTER SUPPORT GRANT

$1,982,572
University Of Virginia Charlottesville · P30 · FY2003 · CA